259 related articles for article (PubMed ID: 23049733)
21. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic significance of apical membranous and cytoplasmic dot-like CD26 expression in encapsulated follicular variant of papillary thyroid carcinoma: a useful marker for capsular invasion.
Takagi S; Hirokawa M; Nagashima K; Higuchi M; Kadota K; Ishikawa R; Sato M; Miyauchi A; Miyake Y; Haba R
Endocr J; 2020 Dec; 67(12):1207-1214. PubMed ID: 32879160
[TBL] [Abstract][Full Text] [Related]
23. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.
Yang X; Hu Y; Shi H; Zhang C; Wang Z; Liu X; Chen H; Zhang L; Cui D
Eur Arch Otorhinolaryngol; 2018 Aug; 275(8):2127-2134. PubMed ID: 29951933
[TBL] [Abstract][Full Text] [Related]
24. Low expression of
Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
[TBL] [Abstract][Full Text] [Related]
25. High Diagnostic Accuracy Based on CLDN10, HMGA2, and LAMB3 Transcripts in Papillary Thyroid Carcinoma.
Barros-Filho MC; Marchi FA; Pinto CA; Rogatto SR; Kowalski LP
J Clin Endocrinol Metab; 2015 Jun; 100(6):E890-9. PubMed ID: 25867809
[TBL] [Abstract][Full Text] [Related]
26. CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma.
Chao TT; Maa HC; Wang CY; Pei D; Liang YJ; Yang YF; Chou SJ; Chen YL
APMIS; 2016 Dec; 124(12):1031-1037. PubMed ID: 27649840
[TBL] [Abstract][Full Text] [Related]
27. Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour.
Pinto AE; Silva GL; Henrique R; Menezes FD; Teixeira MR; Leite V; Cavaco BM
Eur J Endocrinol; 2014 Feb; 170(2):321-7. PubMed ID: 24272198
[TBL] [Abstract][Full Text] [Related]
28. Expression Levels of miR-30a-5p in Papillary Thyroid Carcinoma: A Comparison Between Serum and Fine Needle Aspiration Biopsy Samples.
Igci YZ; Ozkaya M; Korkmaz H; Bozgeyik E; Bayraktar R; Ulasli M; Erkilic S; Eraydin A; Oztuzcu S
Genet Test Mol Biomarkers; 2015 Aug; 19(8):418-23. PubMed ID: 26047355
[TBL] [Abstract][Full Text] [Related]
29. Columnar cell variant of papillary thyroid carcinoma: a study of 10 cases with emphasis on CDX2 expression.
Sujoy V; Pinto A; Nosé V
Thyroid; 2013 Jun; 23(6):714-9. PubMed ID: 23488912
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic Value of TROP2 Expression in Papillary Thyroid Carcinoma.
Saffar H; Jahanbin B; Ameli F; Farhang F; Tavangar SM; Saffar H
Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):218-222. PubMed ID: 33264108
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
32. Development of prognostic signatures for intermediate-risk papillary thyroid cancer.
Brennan K; Holsinger C; Dosiou C; Sunwoo JB; Akatsu H; Haile R; Gevaert O
BMC Cancer; 2016 Sep; 16(1):736. PubMed ID: 27633254
[TBL] [Abstract][Full Text] [Related]
33. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?
Wu G; Wang J; Zhou Z; Li T; Tang F
J Int Med Res; 2013 Aug; 41(4):975-83. PubMed ID: 23857157
[TBL] [Abstract][Full Text] [Related]
34. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
[TBL] [Abstract][Full Text] [Related]
35. Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma.
Das DK; Al-Waheeb SK; George SS; Haji BI; Mallik MK
Diagn Cytopathol; 2014 Jun; 42(6):498-505. PubMed ID: 24273003
[TBL] [Abstract][Full Text] [Related]
36. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
37. The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma.
Zhao Y; Liu X; Zhong L; He M; Chen S; Wang T; Ma S
Int J Mol Med; 2015 Oct; 36(4):1097-103. PubMed ID: 26252081
[TBL] [Abstract][Full Text] [Related]
38. CCNA1 gene as a potential diagnostic marker in papillary thyroid cancer.
da Silva RM; Santos JN; Uno M; Chammas R; Kulcsar MAV; Sant'Anna LB; Canevari RA
Acta Histochem; 2020 Dec; 122(8):151635. PubMed ID: 33007517
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]